Luciana Molinero Selected Research

Luciana Molinero Research Topics

Disease

27	Neoplasms (Cancer) 03/2024 - 02/2014
9	Triple Negative Breast Neoplasms 03/2024 - 11/2018
6	Breast Neoplasms (Breast Cancer) 12/2022 - 01/2016
4	Ovarian Neoplasms (Ovarian Cancer) 10/2023 - 11/2020
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 01/2019
3	Neoplasm Metastasis (Metastasis) 01/2020 - 11/2018
2	Inflammation (Inflammations) 03/2024 - 02/2014
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2023 - 01/2016
2	Neutropenia 10/2021 - 01/2020
2	Disease Progression 10/2019 - 11/2018
2	Melanoma (Melanoma, Malignant) 10/2019 - 09/2017
1	Residual Neoplasm 03/2024
1	Genomic Instability 01/2023
1	Microsatellite Instability 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Anemia 10/2021
1	Hypertension (High Blood Pressure) 10/2021
1	Carcinoma (Carcinomatosis) 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2021
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2021
1	Pneumonia (Pneumonitis) 10/2020
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2020
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020
1	Autoimmune Hepatitis 01/2020
1	Septic Shock (Toxic Shock Syndrome) 01/2020
1	Fatigue 01/2020
1	Liver Failure 01/2020
1	Uterine Neoplasms (Uterine Cancer) 01/2019
1	Glioblastoma (Glioblastoma Multiforme) 11/2018
1	Colonic Neoplasms (Colon Cancer) 02/2014
1	Colitis 02/2014
1	Bronchiolitis Obliterans Syndrome 09/2010
1	Lung Diseases (Lung Disease) 09/2010
1	Glioma (Gliomas) 07/2008
1	Lymphoma (Lymphomas) 04/2008
1	Leukemia 04/2008

Drug/Important Bio-Agent (IBA)

21	atezolizumabIBA 03/2024 - 11/2018
12	Biomarkers (Surrogate Marker)IBA 03/2024 - 09/2010
11	B7-H1 AntigenIBA 03/2024 - 11/2018
7	130-nm albumin-bound paclitaxelIBA 11/2021 - 11/2018
6	Immune Checkpoint InhibitorsIBA 01/2023 - 11/2018
5	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2016
4	Bevacizumab (Avastin)FDA Link 03/2024 - 11/2020
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2008
3	PlatinumIBA 10/2021 - 01/2019
3	LigandsIBA 01/2021 - 01/2019
3	taxaneIBA 10/2020 - 11/2018
2	Carboplatin (JM8)FDA LinkGeneric 12/2021 - 10/2021
2	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 01/2016
2	Phenobarbital (Luminal)FDA Link 01/2016 - 01/2016
1	Interleukin-6 (Interleukin 6)IBA 01/2023
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2023
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 12/2021
1	pertuzumabIBA 12/2021
1	Trastuzumab (Herceptin)FDA Link 12/2021
1	Docetaxel (Taxotere)FDA Link 12/2021
1	Ado-Trastuzumab EmtansineIBA 12/2021
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2020
1	AnthracyclinesIBA 10/2020
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2020
1	Monoclonal AntibodiesIBA 01/2019
1	InterleukinsIBA 01/2019
1	Chemokine CXCL10IBA 01/2019
1	Hormones (Hormone)IBA 11/2018
1	human ERBB2 proteinIBA 11/2018
1	VemurafenibIBA 09/2017
1	cobimetinibIBA 09/2017
1	ParaffinIBA 01/2016
1	Formaldehyde (Formol)FDA Link 01/2016
1	ChromatinIBA 02/2014
1	CateninsIBA 02/2014
1	SurvivinIBA 07/2008
1	LuciferasesIBA 07/2008
1	Guanylate KinasesIBA 04/2008
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 04/2008
1	Protein Kinase C-thetaIBA 04/2008

Therapy/Procedure

12	Therapeutics 03/2024 - 01/2016
5	Immunotherapy 03/2024 - 12/2021
5	Drug Therapy (Chemotherapy) 01/2023 - 01/2019
1	Precision Medicine 01/2016
1	Adjuvant Chemotherapy 01/2016
1	Lung Transplantation 09/2010
1	Radiotherapy 07/2008